KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Change in Accured Expenses: 2010-2024

Historic Change in Accured Expenses for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to -$15.0 million.

  • Supernus Pharmaceuticals' Change in Accured Expenses fell 505.27% to -$36.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.9 million, marking a year-over-year decrease of 469.93%. This contributed to the annual value of -$15.0 million for FY2024, which is 58.62% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Change in Accured Expenses of -$15.0 million as of FY2024, which was up 58.62% from -$36.3 million recorded in FY2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Accured Expenses peaked at $18.2 million during FY2021, and registered a low of -$36.3 million during FY2023.
  • In the last 3 years, Supernus Pharmaceuticals' Change in Accured Expenses had a median value of -$19.2 million in 2022 and averaged -$23.5 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Change in Accured Expenses surged by 188.90% in 2020 and then crashed by 205.41% in 2022.
  • Over the past 5 years, Supernus Pharmaceuticals' Change in Accured Expenses (Yearly) stood at $10.4 million in 2020, then skyrocketed by 75.03% to $18.2 million in 2021, then plummeted by 205.41% to -$19.2 million in 2022, then slumped by 89.36% to -$36.3 million in 2023, then skyrocketed by 58.62% to -$15.0 million in 2024.